Foundational Therapies in IgA Nephropathy

Opinion
Video

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, provide an overview of the foundational therapies approved for treatment of IgAN and their functions.

This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD.

In this transcript, Dr Brad Rovin discusses the pathogenic cascade of IGA nephropathy and highlights multiple intervention points for clinicians. Emphasizing the significance of understanding how these points interact, he underscores the importance of combining therapies to achieve desired outcomes. Dr Rovin notes the current stage of therapy development, indicating promising results in various clinical trials. He categorizes therapeutic agents based on their interaction with the multiple-hit hypothesis in damaging the kidney.

The longstanding focus has been on inhibiting the renal and angiotensin aldosterone system (RAS) to address IGA nephropathy. This involves ACE inhibitors or ARBs, known to improve glomerular hemodynamics and reduce proteinuria. Acknowledging the role of immune aggregates in triggering pathways, he describes these RAS inhibitors as renal protective therapies directly targeting kidney mechanisms.

Dr Rovin introduces a timely development – the approval of a drug targeting the endothelial system in combination with RAS. This drug has demonstrated accelerated approval and significant improvement in reducing proteinuria compared to using an Angiotensin Receptor Blocker alone. Phase three trial results show a preservation of kidney function over a two-year period, with a notable decline in estimated glomerular filtration rate (EGFR).

Overall, the discussion emphasizes the evolving landscape of IGA nephropathy therapy, with a focus on combining renal protective agents and addressing multiple pathways to enhance treatment efficacy.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
Video 1 - Featuring 3 KOLs in, "Recommended targets when treating ulcerative colitis/Crohn’s disease in clinic"
Video 1 - Featuring 3 KOLs in, "Treat-to-target in Inflammatory Bowel Disease"
Kaitlin Mayne, MBChB | Credit X.com
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Fadi Fakhouri, MD, PhD | Credit: University of Lausanne
Helen Colhoun, MD | Credit: University of Edinburgh
Digital illustration of kidneys | Credit: Fotolia
© 2024 MJH Life Sciences

All rights reserved.